Abstract: Recommender systems (RSs) have gained significant attention for their ability to model user preferences and predict future trends. Collaborative filtering (CF), particularly through ...
Novavax secures a non-exclusive licensing deal with Pfizer, validating Matrix-M's platform value and shifting NVAX toward a technology provider model. NVAX receives $30M upfront, a potential $500M in ...
Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine programs. The tech, called Matrix-M, is designed to trigger an immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results